CVS to pay $45M settlement to resolve three lawsuits, AG says
CVS Health has agreed to a $45 million settlement with Louisiana Attorney General Liz Murrill. This resolution addresses three lawsuits accusing CVS of deceptive and anti-competitive practices related to patient text messages, inflated drug prices, and unfair competition against independent pharmacies. The settlement funds will be used to combat Medicaid fraud and implement new pharmacy benefit legislation.
How CVS Health test-drives better care experiences using generative agents
CVS Health is leveraging generative agent simulations to test and refine customer care experiences, using AI-driven "agentic twins" modeled on real patient data. This technology allows them to understand various populations' responses to services and messages, uncover friction points, and prioritize effective interventions more quickly than traditional research. The goal is to design simpler, more intuitive care journeys and improve health outcomes by understanding patient motivations.
McKesson Stock Is Quietly Beating Big Tech – But Is It Built to Last?
McKesson Corporation, a major pharmaceutical distributor in the US, has seen its stock quietly outperform many tech giants, driven by its essential role in the healthcare supply chain, defensive earnings, and strong cash flow. Analysts view McKesson as a long-term healthcare infrastructure play, despite risks like opioid litigation and pricing pressures. The company's resilience, shareholder returns, and focus on specialty medical growth make it attractive to long-term investors seeking stable healthcare exposure rather than high-growth speculative plays.
Weight Management Supplements Market Report 2026: A $15+ Billion Market by 2030 Featuring Leading Players - Nestle, Abbott Laboratories, GSK, Glanbia, Herbalife Nutrition, and Amway - Forecast to 2035
The weight management supplements market is experiencing significant growth, projected to reach $15.08 billion by 2030 from $7.88 billion in 2026, driven by factors like increasing obesity rates, consumer focus on wellness, and personalized nutrition demand. Key trends include plant-based and botanical supplements, digital health integration, and online sales. Leading companies such as Nestle, Abbott, and Herbalife Nutrition are innovating with new products and strategic acquisitions to capitalize on market opportunities globally.
Seattle Reign land new sponsor ahead of 2026 season
The Seattle Reign FC has secured CVS Health as a new sponsor, with the healthcare company's branding set to appear on the team's pitch and as the first right-sleeve sponsor on their jerseys. This deal marks a significant partnership for the Reign ahead of their 2026 season.
UnitedHealth stock edges up near $290 as Medicare Advantage shakeout returns to spotlight
UnitedHealth (UNH) stock edged up by 0.5% to $289.57, performing better than the general U.S. market, as the challenges within the Medicare Advantage program are highlighted. A recent study revealed that nearly 3 million Medicare Advantage members were forced to switch plans for 2026 due to insurers exiting markets or reducing options, with UnitedHealthcare accounting for a significant portion of these changes. Investors are closely monitoring the Centers for Medicare & Medicaid Services' (CMS) upcoming decisions on 2027 Medicare Advantage payment rates, alongside ongoing concerns about medical costs and cybersecurity risks affecting UnitedHealth's Change Healthcare unit.
CVS goes all-in on women's soccer with multi-city field initiative
CVS Health is expanding its commitment to women's soccer through a new collaboration with U.S. Soccer and the NWSL. This initiative includes backing youth soccer clinics and funding the construction of new soccer fields in several U.S. metropolitan areas. The company is currently a sponsor of three NWSL teams.
CVS Pharmacy community health partnership with U.S. Soccer and National Women's Soccer League
CVS Pharmacy has announced a multi-year partnership with the U.S. Soccer Federation and the National Women’s Soccer League (NWSL) to promote community health and wellness. This initiative includes a significant investment in developing multi-use community soccer fields in select markets through 2028 and club-specific sponsorships with the Seattle Reign FC and Kansas City Current, building on an existing partnership with the Washington Spirit. The collaboration aims to foster healthier communities by expanding access to sports, safe play spaces, and community connection, with support from NWSL icon Alex Morgan.
Sysco sued over alleged unlawful tobacco surcharge in employee health plans
Sysco is facing a class action lawsuit alleging it unlawfully imposed a discriminatory and punitive health insurance surcharge on employees who use tobacco products. Plaintiffs argue that Sysco violated ERISA by charging a $23.08 biweekly "tobacco surcharge" without offering a compliant wellness program or a reasonable alternative standard to avoid the charge. The lawsuit claims this practice disproportionately burdens low-income workers and seeks to represent a nationwide class of affected individuals who paid the surcharge since 2014.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report fourth-quarter 2025 results with an estimated loss of 19 cents per share on revenues of $633.91 million. While the company's Q4 earnings estimate has improved and anticipates a significant year-over-year EPS improvement for 2025, revenue is expected to decline. The strength in U.S. Integrated Care membership and adjusted EBITDA from this segment is a positive, but declines in access fees, U.S. operations revenue, and BetterHelp contributions pose challenges.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report its Q4 2025 earnings on February 25, 2026, with a Zacks Consensus Estimate of a loss of 19 cents per share on revenues of $633.91 million. While adjusted EPS is expected to show significant year-over-year improvement, revenue is anticipated to decline. The company's U.S. Integrated Care segment shows promising growth, potentially offsetting declines in BetterHelp and overall access fees.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report its Q4 2025 earnings on February 25, 2026, with analysts expecting a loss of 19 cents per share on revenues of $633.91 million. While the company has a mixed earnings beat history, its U.S. Integrated Care segment is anticipated to show significant growth in members and adjusted EBITDA, potentially offsetting declines in other areas like BetterHelp and overall access fees. The article also provides a comparison with other medical sector companies, CVS Health and Doximity.
CVS Pharmacy Partners with U.S. Soccer Federation and National Women's Soccer League to Promote Community Health and Wellness
CVS Pharmacy has announced a multi-year partnership with the U.S. Soccer Federation and the National Women's Soccer League (NWSL) to promote community health and wellness. This collaboration includes a significant investment in developing community multi-use soccer fields across the country and expanding existing relationships with clubs like the Washington Spirit, Seattle Reign FC, and Kansas City Current. The initiative aims to provide accessible spaces for play and connection, supported by NWSL icon Alex Morgan and U.S. Soccer ambassadors.
CVS will fund new community soccer fields with U.S. women’s league
CVS Pharmacy has become an Official Health and Wellness Partner of the U.S. Soccer Federation and the National Women's Soccer League (NWSL). This multi-year partnership includes a significant investment to develop community multi-use soccer fields in select U.S. markets through 2028. Additionally, CVS will sponsor NWSL clubs like Washington Spirit, Seattle Reign FC, and Kansas City Current, promoting community wellness initiatives amplified by athletes such as Alex Morgan.
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2025 Earnings Call Transcript
Bausch + Lomb (NYSE:BLCO) reported strong Q4 2025 results, with 7% constant currency revenue growth and 27% adjusted EBITDA growth, driven by strategic execution and a focus on financial excellence. The company exceeded expectations for its dry eye portfolio, particularly Miebo, and provided optimistic 2026 guidance anticipating continued revenue growth and significant EBITDA margin expansion. Leadership emphasized a commitment to innovation, disciplined investment, and leveraging a streamlined cost structure to achieve long-term financial targets.
Teladoc Q4 Earnings: Can Integrated Care Strength Save Profits?
Teladoc Health (TDOC) is projected to report its Q4 2025 earnings on February 25, 2026, with the Zacks Consensus Estimate expecting a loss of 19 cents per share on revenues of $633.91 million. While overall revenues are predicted to decrease, the company's Integrated Care segment is expected to show significant growth in members and adjusted EBITDA, potentially offsetting declines in other areas like BetterHelp. The article also notes that Teladoc's earnings surprise average is 14.5% over the past four quarters.
New Haven sues Cigna, CVS Health, UnitedHealth over insulin pricing scheme
The City of New Haven has filed a RICO lawsuit against Cigna, CVS Health, UnitedHealth, and three insulin manufacturers, alleging a scheme to artificially inflate insulin prices between 2010 and 2019. The lawsuit claims that manufacturers set high list prices and funneled secret rebates and administrative fees to Pharmacy Benefit Managers (PBMs) in exchange for preferred formulary placement, leading to inflated costs for self-insured health plans. New Haven is seeking treble damages, disgorgement, punitive damages, and injunctive relief, claiming violations of federal and state antitrust and unfair trade practices acts.
Goodpath Launches Direct-to-Employer and Self-Pay Wegovy Access With Novo Nordisk Partnership
Goodpath has partnered with Novo Nordisk to offer direct-to-employer and self-pay options for Wegovy (both injectable and oral versions), aiming to provide employers with transparent GLP-1 pricing and control over subsidy levels. This initiative bypasses traditional PBM structures, integrating Wegovy into a comprehensive "whole-person" weight care model that also addresses comorbidities. Goodpath projects this direct-to-employer program could reduce obesity medication costs by 35% or more while ensuring clinical oversight and support for patients.
HCA Florida Healthcare opens ER in Shoppes at Mission Trace
HCA Florida Healthcare has opened a new freestanding emergency room in St. Augustine, located at 1780 Woodlawn Road within the Shoppes at Mission Trace. This 860-square-foot facility, costing approximately $14.8 million to build, is the health care group’s second ER in St. Johns County. It operates 24/7, offering 10 private rooms, a trauma bay, and various diagnostic services to enhance access to emergency care in the community.
UnitedHealth Group: A Top Healthcare Stock for the Next Decade
UnitedHealth Group's stock has declined over 41% in the past year due to various challenges, including disappointing earnings and potential Medicare changes. Despite this, the company benefits from vertical integration, diverse revenue streams through its insurance and Optum segments, and significant scale effects in the healthcare sector. Wall Street analysts forecast a rise in UNH's stock price, with an average target of $397.82, amidst ongoing adjustments to price targets by firms like Mizuho and JPMorgan.
How CVS Health is supporting heart health through prevention and chronic management
CVS Health is addressing heart disease, the leading cause of death in the U.S., through a multi-faceted approach focusing on prevention, early detection, and chronic management. Their services include convenient preventive screenings, personalized weight loss and lifestyle support, and specialized care coordination through MinuteClinic, Oak Street Health, and Signify Health. The company aims to make heart health initiatives more accessible to Americans.
CVS puts $5M toward training more homegrown pharmacists in Louisiana
CVS Health has launched a $5 million scholarship program for Doctor of Pharmacy (PharmD) students in Louisiana, aiming to reduce financial barriers and strengthen the state's pharmacy workforce. The program will support students at Xavier University of Louisiana and the University of Louisiana at Monroe, with scholarships becoming available in the 2026-27 academic year. This initiative aligns with CVS Health's broader commitment to health equity and workforce development, investing in local talent to expand access to care in underserved communities.
Cigna’s Evernorth drops TMS pre-approvals, speeding depression care
BrainsWay (NASDAQ: BWAY) has announced that Cigna's Evernorth Behavioral Health will eliminate prior authorization requirements for transcranial magnetic stimulation (TMS) for contracted providers, effective March 6, 2026. This change is expected to accelerate patient access to TMS for major depressive disorder and OCD for over 18 million covered lives across 12 states. The company views this as a significant step in reducing administrative barriers and expanding access to its Deep TMS systems.
Baird's Model Update Suggests Alignment Healthcare, Inc. (ALHC)'s Shares Could Reach $59
Baird has updated its model for Alignment Healthcare, Inc. (ALHC), increasing its price target to $59 from $28 and reiterating an Outperform rating. This suggests a potential 163% upside from its current price. Despite a recent insider sale by CEO John E. Kao, analysts predict profitability for ALHC this year with an expected FY2025 EPS of $0.23.
Humana’s CenterWell buys primary care provider MaxHealth
Humana's health services division, CenterWell, has acquired MaxHealth, a primary care provider based in Florida, from private equity firm Arsenal Capital Partners. This acquisition adds 82 clinics (54 owned, 24 affiliated, 4 specialty/ancillary) to CenterWell's portfolio, serving over 120,000 patients and further expanding Humana's primary care business, particularly in value-based care arrangements. The move aligns with Humana's strategy to grow its primary care footprint, though financial details of the deal were not disclosed.
Capital One Bank Review 2025
This Bankrate review of Capital One Bank for 2025 highlights its suitability for individuals seeking online banking benefits like competitive rates on savings and CDs, no monthly fees, and a wide ATM network. It details the bank's products, including the 360 Performance Savings, 360 Certificates of Deposit, and 360 Checking accounts, along with their respective pros and cons and historical rate changes. The review also covers Capital One's customer experience, including physical presence, customer support, digital experience, and recent complaints such as a data breach fine and a CFPB lawsuit that was later dropped.
Genco Shipping & Trading Limited (NYSE:GNK) Short Interest Down 13.4% in January
Genco Shipping & Trading Limited (NYSE:GNK) experienced a 13.4% decrease in short interest in January, totaling 1,244,904 shares by January 30th. This represents 2.9% of shares short and a 3.8-day short-interest ratio. The stock traded down 1.3% to $21.93, nearing its 52-week high, while analysts maintain a "Buy" rating with a $21.00 target price and institutional ownership remains high at 58.62%.
Aetna Joins Humana and United Healthcare in Expanding Medicare Advantage Coverage for ReWalk Personal Exoskeleton
Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton for eligible beneficiaries with spinal cord injuries. This expansion by three major insurers, covering approximately 16 million beneficiaries, signifies a significant step in recognizing the device's medical necessity and improving access to advanced rehabilitation technology. The ReWalk system, developed by Lifeward Ltd., is FDA-approved and has demonstrated benefits in ambulation, musculoskeletal health, and cardiopulmonary function, promoting independence and dignity for users.
The Top 5 Analyst Questions From CVS Health's Q4 Earnings Call
CVS Health reported strong Q4 2025 results, exceeding analyst expectations in revenue, adjusted EPS, and EBITDA, driven by operational efficiency and successful integration of Rite Aid assets. The article highlights the top five analyst questions from the earnings call, covering topics such as Medicare Advantage rate impacts, FTC legislation, competitive outlook, commercial membership growth, and technology investment timing. These questions and management's responses offer insights into CVS's strategies and challenges moving forward.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During volatile market conditions, dividend-yielding healthcare stocks like UnitedHealth Group, Viatris, and CVS Health can be attractive to investors due to their high free cash flows and regular payouts. This article highlights the ratings and price targets from top-performing analysts for these three companies. Analysts from Mizuho, Truist Securities, Piper Sandler, Barclays, B of A Securities, and JP Morgan have provided recent evaluations and price targets for these stocks, which each offer a dividend yield over 3%.
Humana’s CenterWell buys primary care provider MaxHealth
Humana's health services division, CenterWell, has acquired primary care provider MaxHealth from Arsenal Capital Partners, continuing its expansion in the primary care market. MaxHealth operates 54 clinics in Florida, serving over 120,000 patients, with financial terms undisclosed. This acquisition strengthens CenterWell's portfolio, which increased its patient base by over 25% in the past year, amid a challenging environment where other major insurers like CVS and UnitedHealth have faced setbacks in their care delivery operations.
Is State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
The article evaluates the State Street SPDR Portfolio S&P 500 High Dividend ETF (SPYD), highlighting it as a smart beta ETF focused on large-cap value with a high dividend yield. It details the fund's objective to track the S&P 500 High Dividend Index, its low expense ratio of 0.07%, and its sector allocations, including top holdings like CVS Health Corp. The report concludes that SPYD is a strong option for investors seeking to outperform the Style Box - Large Cap Value segment, offering diversified exposure and solid performance.
Inspira™ Technologies Prepares its First Life-Support Systems for Deployment at a Leading U.S. Hospital
Inspira Technologies has delivered its INSPIRA™ ART100 respiratory support systems to Glo-Med Networks for deployment at a major U.S. hospital. This move aims to enhance patient care with innovative life-support technology and direct team support from Inspira. The ART100 system, which revolutionizes cardiopulmonary bypass, will integrate with HYLA™ blood monitoring, showcasing Inspira's commitment to transforming mechanical ventilation.
Humana’s 2026 Guidance and the Crisis in Managed Care
Humana's 2026 financial guidance has revealed a challenging outlook for the managed-care sector, driven by stricter regulations, reduced quality-based bonus payments, and higher medical utilization. The company projects significantly lower earnings per share due to a "star ratings cliff" and increased Medical Loss Ratio, shifting the industry's focus from growth to margin preservation. While Humana targets membership growth, competitors like UnitedHealth Group prioritize margin, and CVS Health stands to benefit from higher star ratings, indicating a critical period of structural change and potential M&A activity in Medicare Advantage.
Kroger & CVS roll out huge shelf change as new era for in-store shopping begins
Kroger and CVS Pharmacy are introducing digital screens on end caps in their stores, marking a significant shift in in-store advertising. This technology allows for dynamic content, such as product videos, seasonal promotions, and educational messaging, aiming to enhance the shopping experience and drive sales. CVS has already deployed screens in over 600 locations, while Kroger is prioritizing grocery aisles and health/beauty sections, viewing end caps as a crucial point of influence for customer engagement.
Sen. John Boozman Buys First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) Shares
Senator John Boozman (R-Arkansas) purchased shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on January 23, 2026, with a value between $1,001 and $15,000. FTGC recently declared a significantly increased quarterly dividend of $3.6647, leading to an annualized yield of approximately 60%. Boozman also made several other small trades in late January, including purchases of Eaton, Caterpillar, CVS, PayPal, and DexCom, and sales of Omnicom, an S&P 500 growth ETF (IVW), Fiserv, Union Pacific, and Micron.
Sen. John Boozman Buys Exxon Mobil Corporation (NYSE:XOM) Shares
Senator John Boozman recently purchased shares of Exxon Mobil (NYSE: XOM), with the transaction disclosed on February 15th for shares bought on January 8th. The oil giant exceeded Q4 earnings estimates with $1.71 EPS against $1.63 and revenue of $82.31 billion against $77.98 billion, also declaring a quarterly dividend of $1.03 per share. Despite recent buying activity from institutional investors and Sen. Boozman, Exxon Mobil currently has a "Hold" consensus rating from analysts.
The UnitedHealth Reset: Analyzing the 3.1% Surge and the Future of the Dow’s Healthcare Titan
UnitedHealth Group (UNH) experienced a 3.1% surge on February 13, 2026, offering a glimmer of hope after a significant stock decline earlier in the year. This report examines whether this rally signifies a definitive bottom for the healthcare giant or if regulatory and operational challenges in 2026 will persist. The article details UNH's business model, financial performance, leadership changes, and the competitive landscape, concluding that 2026 is a "Reset Year" for the company amid intensified scrutiny and lower government reimbursements.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
ResMed (RMD) shares have underperformed the S&P 500 significantly over the last six months, prompting investors to reevaluate the stock. The company shows positive attributes including consistent currency revenue growth, strong long-term EPS growth, and an increasing free cash flow margin. Despite its recent drawdown, ResMed's stock trades at 21.1x forward P/E, leading to questions about its current buying opportunity.
Is CVS Health Corporation (CVS) Larry Robbins' top pick?
CVS Health Corporation (NYSE: CVS) is highlighted as Larry Robbins' top stock pick, accounting for a significant portion of his portfolio. Despite a decrease in fourth-quarter profit, CVS exceeded Wall Street expectations, showcasing early success in restructuring efforts. The company reaffirmed its revenue guidance for 2026, indicating a focus on execution discipline.
Invesco 2028 Bond ETF Emerges as a Steady Anchor Amid Market Turndown
The Invesco BulletShares 2028 Corporate Bond ETF (NYSE: BSCJ) has garnered renewed investor interest as US Treasuries dipped to new annual lows and equity markets experienced heightened volatility. The ETF's focus on high-grade corporate debt offers a steady anchor with notable resilience, evidenced by stable spreads and gains in the Bloomberg Credit Index. Key factors influencing its near-term path include upcoming Federal Reserve meetings, monthly rebalancing, credit spread volatility, and inflation readings.
Jim Cramer Discusses CVS Health (CVS) In Detail
Jim Cramer highlighted CVS Health (CVS) as a promising investment, noting its strong position against competitors like Walgreens and Rite Aid and its diversified business model, including Aetna. Despite recent analyst price target adjustments due to Medicare/Medicaid reimbursement concerns, Cramer emphasized CVS's potential for growth. The article also briefly mentioned that some AI stocks might offer even greater returns with less downside risk.
CVS Pharmacy Is Quietly Becoming Your All?in?One Health Hub – Here’s Why It Matters Now
CVS Pharmacy is transforming into a comprehensive health and convenience hub, offering prescriptions, vaccinations, same-day delivery, and telehealth to simplify healthcare for consumers. The company's strategy combines physical stores, digital tools via CVS.com and its app, and clinical services to create a single ecosystem for managing health needs. While the integrated platform is praised for convenience, customer experience can vary based on individual store performance.
CVS Health Corporation (NYSE:CVS) is favoured by institutional owners who hold 88% of the company
Institutional investors hold a significant 88% stake in CVS Health Corporation, indicating their strong confidence in the company and potential influence on its stock price. A collective group of 13 investors accounts for 50% ownership, with BlackRock Inc. being the largest shareholder at 9.5%. Insiders, including board members, own less than 1% of the shares, while the general public holds about 12%.
Invesco 2028 Bond ETF Emerges as a Steady Anchor Amid Market Turndown
The Invesco BulletShares 2028 Corporate Bond ETF has shown remarkable stability amidst recent equity market volatility, attracting renewed investor interest. With a low effective duration and a portfolio of high-grade corporate debt, the ETF demonstrates resilience. Investors are closely watching upcoming Federal Reserve meetings, inflation readings, and market dynamics to gauge its future performance.
Jim Cramer Discusses CVS Health (CVS) In Detail
Jim Cramer discussed CVS Health (CVS), highlighting its strong position against competitors like Walgreens and Rite Aid due to its diversified business model, including Aetna. While analysts have slightly trimmed price targets due to Medicare/Medicaid reimbursement concerns, Cramer sees benefits from pharmaceutical retail industry developments. CVS shares are up 19.2% over the past year and Cramer is optimistic, noting its upcoming earnings report.
First Trust Dorsey Wright Focus 5 ETF $FV Shares Bought by Ameritas Advisory Services LLC
Ameritas Advisory Services LLC increased its stake in the First Trust Dorsey Wright Focus 5 ETF (NASDAQ:FV) by 88.2% during the third quarter, bringing its total holdings to 23,922 shares worth $1,481,000. Other institutions like Daymark Wealth Partners LLC and Geneos Wealth Management Inc. also significantly increased their positions. The ETF recently declared a quarterly dividend of $0.1355 per share, an increase from its previous dividend, and trades with a market capitalization of $3.60 billion.
Las Vegas Sands Promotes Patrick Dumont To Succeed Robert Goldstein As Chairman And CEO
Las Vegas Sands Corp. announced that Patrick Dumont will take over as Chairman and CEO, effective March 1, 2026, succeeding Robert Goldstein. Dumont, who has been with the company since 2010 and served as President and COO since 2021, will also chair Sands China Ltd. Goldstein will transition to a senior advisor role through March 2028.
Do Insider Sales at Alignment Healthcare (ALHC) Complicate the Story of Its Rapid Membership Expansion?
Alignment Healthcare (ALHC) recently reported strong health plan membership growth and projected further expansion, while its CEO and CHRO conducted routine share sales. The article examines whether these insider sales complicate the narrative of the company's rapid growth, emphasizing that strong membership momentum and analyst upgrades are shaping investor expectations. However, it also highlights the importance of the company's technology initiatives and the potential impact of regulatory changes on its profitability.
12 Youngest Hedge Fund Billionaires and Their Top Stock Picks
This article focuses on David Einhorn, one of the featured hedge fund billionaires, and highlights his top stock pick: Green Brick Partners, Inc. (NYSE:GRBK). It details the company's strong performance, recent accolades for its master-planned communities, and its strategy in high-growth housing markets. The piece emphasizes Green Brick Partners' disciplined land strategy and resilient demand as key drivers of its success.
